請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77837
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李克昭(Ker-Chau Li) | |
dc.contributor.author | Kang-Chung Yang | en |
dc.contributor.author | 楊剛仲 | zh_TW |
dc.date.accessioned | 2021-07-11T14:35:45Z | - |
dc.date.available | 2022-09-04 | |
dc.date.copyright | 2017-09-04 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-08-20 | |
dc.identifier.citation | Abrahamowicz, M., Bartlett, G., Tamblyn, R., & du Berger, R. (2006). Modeling cumulative dose and exposure duration provided insights regarding the associations between benzodiazepines and injuries. J Clin Epidemiol, 59(4), 393-403. doi:10.1016/j.jclinepi.2005.01.021
Abrahamowicz, M., Beauchamp, M. E., & Sylvestre, M. P. (2012). Comparison of alternative models for linking drug exposure with adverse effects. Stat Med, 31(11-12), 1014-1030. doi:10.1002/sim.4343 Andersen, S. M., Randers, A., Jensen, C. M., Bisgaard, C., & Steinhausen, H. C. (2013). Preceding diagnoses to young adult bipolar disorder and schizophrenia in a nationwide study. BMC Psychiatry, 13, 343. doi:10.1186/1471-244X-13-343 Atzori, P., Usala, T., Carucci, S., Danjou, F., & Zuddas, A. (2009). Predictive factors for persistent use and compliance of immediate-release methylphenidate: a 36-month naturalistic study. J Child Adolesc Psychopharmacol, 19(6), 673-681. doi:10.1089/cap.2008.0146 Austin, P. C., & Tu, J. V. (2004). Bootstrap methods for developing predictive models. The American Statistician, 58(2), 131-137. Azoulay, L., Filion, K. B., Platt, R. W., Dahl, M., Dormuth, C. R., Clemens, K. K., . . . Ernst, P. (2016). Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. Bmj, 352, i581. doi:10.1136/bmj.i581 Becker, S. P., Luebbe, A. M., & Langberg, J. M. (2012). Co-occurring mental health problems and peer functioning among youth with attention-deficit/hyperactivity disorder: a review and recommendations for future research. Clin Child Fam Psychol Rev, 15(4), 279-302. doi:10.1007/s10567-012-0122-y Biederman, J., Ball, S. W., Monuteaux, M. C., Mick, E., Spencer, T. J., McCreary, M., . . . Faraone, S. V. (2008). New insights into the comorbidity between ADHD and major depression in adolescent and young adult females. J Am Acad Child Adolesc Psychiatry, 47(4), 426-434. doi:10.1097/CHI.0b013e31816429d3 Biederman, J., Faraone, S., Milberger, S., Guite, J., Mick, E., Chen, L., . . . Perrin, J. (1996). A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry, 53(5), 437-446. Biederman, J., & Faraone, S. V. (2005). Attention-deficit hyperactivity disorder. The Lancet, 366(9481), 237-248. doi:10.1016/s0140-6736(05)66915-2 Biederman, J., Monuteaux, M. C., Mick, E., Spencer, T., Wilens, T. E., Silva, J. M., . . . Faraone, S. V. (2006). Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med, 36(2), 167-179. doi:10.1017/S0033291705006410 Biederman, J., Monuteaux, M. C., Spencer, T., Wilens, T. E., & Faraone, S. V. (2009). Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics, 124(1), 71-78. doi:10.1542/peds.2008-3347 Biederman, J., Petty, C. R., Dolan, C., Hughes, S., Mick, E., Monuteaux, M. C., & Faraone, S. V. (2008). The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study. Psychol Med, 38(7), 1027-1036. doi:10.1017/S0033291707002668 Breslow, N. E., & Day, N. E. (1987). Statistical methods in cancer research. Volume II--The design and analysis of cohort studies. IARC Sci Publ(82), 1-406. Brookshire, B. R., & Jones, S. R. (2012). Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine. Synapse, 66(9), 844-847. doi:10.1002/syn.21569 Bruchmuller, K., Margraf, J., & Schneider, S. (2012). Is ADHD diagnosed in accord with diagnostic criteria? Overdiagnosis and influence of client gender on diagnosis. J Consult Clin Psychol, 80(1), 128-138. doi:10.1037/a0026582 Chen, M. H., Lan, W. H., Bai, Y. M., Huang, K. L., Su, T. P., Tsai, S. J., . . . Hsu, J. W. (2016). Influence of Relative Age on Diagnosis and Treatment of Attention-Deficit Hyperactivity Disorder in Taiwanese Children. J Pediatr, 172, 162-167 e161. doi:10.1016/j.jpeds.2016.02.012 Chen, M. H., Su, T. P., Chen, Y. S., Hsu, J. W., Huang, K. L., Chang, W. H., . . . Bai, Y. M. (2013). Higher risk of developing mood disorders among adolescents with comorbidity of attention deficit hyperactivity disorder and disruptive behavior disorder: a nationwide prospective study. J Psychiatr Res, 47(8), 1019-1023. doi:10.1016/j.jpsychires.2013.04.005 Cheng, C. L., Kao, Y. H., Lin, S. J., Lee, C. H., & Lai, M. L. (2011). Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf, 20(3), 236-242. doi:10.1002/pds.2087 Cheng, J. Y., Chen, R. Y., Ko, J. S., & Ng, E. M. (2007). Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacology (Berl), 194(2), 197-209. doi:10.1007/s00213-007-0840-x Chien, I. C., Lin, C. H., Chou, Y. J., & Chou, P. (2012). Prevalence, incidence, and stimulant use of attention-deficit hyperactivity disorder in Taiwan, 1996-2005: a national population-based study. Soc Psychiatry Psychiatr Epidemiol, 47(12), 1885-1890. doi:10.1007/s00127-012-0501-1 Cichon, S., Craddock, N., Daly, M., Faraone, S. V., Gejman, P. V., Kelsoe, J., . . . Sullivan, P. F. (2009). Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry, 166(5), 540-556. doi:10.1176/appi.ajp.2008.08091354 Coon, E. R., Quinonez, R. A., Moyer, V. A., & Schroeder, A. R. (2014). Overdiagnosis: how our compulsion for diagnosis may be harming children. Pediatrics, 134(5), 1013-1023. doi:10.1542/peds.2014-1778 Dalsgaard, S., Mortensen, P. B., Frydenberg, M., Maibing, C. M., Nordentoft, M., & Thomsen, P. H. (2014). Association between Attention-Deficit Hyperactivity Disorder in childhood and schizophrenia later in adulthood. Eur Psychiatry, 29(4), 259-263. doi:10.1016/j.eurpsy.2013.06.004 Daviss, W. B. (2008). A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment. J Child Adolesc Psychopharmacol, 18(6), 565-571. doi:10.1089/cap.2008.032 Dell'Osso, B., Palazzo, M. C., Oldani, L., & Altamura, A. C. (2011). The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci Ther, 17(6), 723-732. doi:10.1111/j.1755-5949.2010.00217.x Di Trani, M., Di Roma, F., Andriola, E., Leone, D., Parisi, P., Miano, S., & Donfrancesco, R. (2014). Comorbid Depressive Disorders in ADHD: The Role of ADHD Severity, Subtypes and Familial Psychiatric Disorders. Psychiatry Investig, 11(2), 137-142. doi:10.4306/pi.2014.11.2.137 Diler, R. S., Daviss, W. B., Lopez, A., Axelson, D., Iyengar, S., & Birmaher, B. (2007). Differentiating major depressive disorder in youths with attention deficit hyperactivity disorder. J Affect Disord, 102(1-3), 125-130. doi:10.1016/j.jad.2007.01.002 Ding, Y. S., Naganawa, M., Gallezot, J. D., Nabulsi, N., Lin, S. F., Ropchan, J., . . . Laruelle, M. (2014). Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD. Neuroimage, 86, 164-171. doi:10.1016/j.neuroimage.2013.08.001 Elia, J., Gai, X., Xie, H. M., Perin, J. C., Geiger, E., Glessner, J. T., . . . White, P. S. (2010). Rare structural variants found in attention-deficit hyperactivity disorder are preferentially associated with neurodevelopmental genes. Mol Psychiatry, 15(6), 637-646. doi:10.1038/mp.2009.57 Elia, J., Glessner, J. T., Wang, K., Takahashi, N., Shtir, C. J., Hadley, D., . . . Hakonarson, H. (2011). Genome-wide copy number variation study associates metabotropic glutamate receptor gene networks with attention deficit hyperactivity disorder. Nat Genet, 44(1), 78-84. doi:10.1038/ng.1013 ENCePP. (2010). The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Guide on Methodological Standards in Pharmacoepidemiology (Revision 5). EMA, 95098. Faraone, S. V., Perlis, R. H., Doyle, A. E., Smoller, J. W., Goralnick, J. J., Holmgren, M. A., & Sklar, P. (2005). Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry, 57(11), 1313-1323. doi:10.1016/j.biopsych.2004.11.024 Garfield, C. F., Dorsey, E. R., Zhu, S., Huskamp, H. A., Conti, R., Dusetzina, S. B., . . . Alexander, G. C. (2012). Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010. Acad Pediatr, 12(2), 110-116. doi:10.1016/j.acap.2012.01.003 Gau, S. S., Chong, M. Y., Chen, T. H., & Cheng, A. T. (2005). A 3-year panel study of mental disorders among adolescents in Taiwan. Am J Psychiatry, 162(7), 1344-1350. doi:10.1176/appi.ajp.162.7.1344 Ghose, S., Winter, M. K., McCarson, K. E., Tamminga, C. A., & Enna, S. J. (2011). The GABAB receptor as a target for antidepressant drug action. Br J Pharmacol, 162(1), 1-17. doi:10.1111/j.1476-5381.2010.01004.x Gibson, A. P., Bettinger, T. L., Patel, N. C., & Crismon, M. L. (2006). Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Ann Pharmacother, 40(6), 1134-1142. doi:10.1345/aph.1G582 Gizer, I. R., Ficks, C., & Waldman, I. D. (2009). Candidate gene studies of ADHD: a meta-analytic review. Hum Genet, 126(1), 51-90. doi:10.1007/s00439-009-0694-x Golubchik, P., Kodesh, A., & Weizman, A. (2013). Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood? Clin Neuropharmacol, 36(5), 141-145. doi:10.1097/WNF.0b013e31829eb204 Gordon, J. A., & Hen, R. (2006). TREKing toward new antidepressants. Nat Neurosci, 9(9), 1081-1083. doi:10.1038/nn0906-1081 Grambsch, P. M., & Therneau, T. M. (1994). Proportional hazards tests and diagnostics based on weighted residuals. Biometrika, 81(3), 515-526. doi:10.1093/biomet/81.3.515 Hamshere, M. L., Stergiakouli, E., Langley, K., Martin, J., Holmans, P., Kent, L., . . . Craddock, N. (2013). Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. Br J Psychiatry, 203(2), 107-111. doi:10.1192/bjp.bp.112.117432 Hauptmann, M., Wellmann, J., Lubin, J. H., Rosenberg, P. S., & Kreienbrock, L. (2000). Analysis of exposure-time-response relationships using a spline weight function. Biometrics, 56(4), 1105-1108. Hesson, J., & Fowler, K. (2015). Prevalence and Correlates of Self-Reported ADD/ADHD in a Large National Sample of Canadian Adults. J Atten Disord. doi:10.1177/1087054715573992 Heurteaux, C., Lucas, G., Guy, N., El Yacoubi, M., Thummler, S., Peng, X. D., . . . Lazdunski, M. (2006). Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci, 9(9), 1134-1141. doi:10.1038/nn1749 Hoffmann, F. (2009). Review on use of German health insurance medication claims data for epidemiological research. Pharmacoepidemiol Drug Saf, 18(5), 349-356. doi:10.1002/pds.1721 Holden, S. E., Jenkins-Jones, S., Poole, C. D., Morgan, C. L., Coghill, D., & Currie, C. J. (2013). The prevalence and incidence, resource use and financial costs of treating people with attention deficit/hyperactivity disorder (ADHD) in the United Kingdom (1998 to 2010). Child Adolesc Psychiatry Ment Health, 7(1), 34. doi:10.1186/1753-2000-7-34 Huang, C. L., Chu, C. C., Cheng, T. J., & Weng, S. F. (2014). Epidemiology of treated attention-deficit/hyperactivity disorder (ADHD) across the lifespan in Taiwan: a nationwide population-based longitudinal study. PLoS One, 9(4), e95014. doi:10.1371/journal.pone.0095014 Huang, Y. W., Lee, C. L., Yang, S. S., Fu, S. C., Chen, Y. Y., Wang, T. C., . . . Chen, D. S. (2016). Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. Am J Gastroenterol, 111(7), 976-985. doi:10.1038/ajg.2016.179 Jansen, R., Penninx, B. W., Madar, V., Xia, K., Milaneschi, Y., Hottenga, J. J., . . . Sullivan, P. F. (2016). Gene expression in major depressive disorder. Mol Psychiatry, 21(3), 339-347. doi:10.1038/mp.2015.57 Jerrell, J. M., McIntyre, R. S., & Park, Y. M. (2015). Risk factors for incident major depressive disorder in children and adolescents with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry, 24(1), 65-73. doi:10.1007/s00787-014-0541-z Kalueff, A. V., Gallagher, P. S., & Murphy, D. L. (2006). Are serotonin transporter knockout mice 'depressed'?: hypoactivity but no anhedonia. Neuroreport, 17(12), 1347-1351. doi:10.1097/01.wnr.0000230514.08962.76 Klein, R. G., Mannuzza, S., Olazagasti, M. A., Roizen, E., Hutchison, J. A., Lashua, E. C., & Castellanos, F. X. (2012). Clinical and functional outcome of childhood attention-deficit/hyperactivity disorder 33 years later. Arch Gen Psychiatry, 69(12), 1295-1303. doi:10.1001/archgenpsychiatry.2012.271 Kraemer, M., Uekermann, J., Wiltfang, J., & Kis, B. (2010). Methylphenidate-induced psychosis in adult attention-deficit/hyperactivity disorder: report of 3 new cases and review of the literature. Clin Neuropharmacol, 33(4), 204-206. doi:10.1097/WNF.0b013e3181e29174 Lakhan, S. E., & Kirchgessner, A. (2012). Prescription stimulants in individuals with and without attention deficit hyperactivity disorder: misuse, cognitive impact, and adverse effects. Brain Behav, 2(5), 661-677. doi:10.1002/brb3.78 Larsson, H., Ryden, E., Boman, M., Langstrom, N., Lichtenstein, P., & Landen, M. (2013). Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. Br J Psychiatry, 203(2), 103-106. doi:10.1192/bjp.bp.112.120808 Lee, K. Y., Royston, S. E., Vest, M. O., Ley, D. J., Lee, S., Bolton, E. C., & Chung, H. J. (2015). N-methyl-D-aspartate receptors mediate activity-dependent down-regulation of potassium channel genes during the expression of homeostatic intrinsic plasticity. Mol Brain, 8, 4. doi:10.1186/s13041-015-0094-1 Lee, M. J., Yang, K. C., Shyu, Y. C., Yuan, S. S., Yang, C. J., Lee, S. Y., . . . Wang, L. J. (2016). Attention-deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: A nationwide population-based study in Taiwan. J Affect Disord, 189, 110-117. doi:10.1016/j.jad.2015.09.015 Lee, S. H., Ripke, S., Neale, B. M., Faraone, S. V., Purcell, S. M., Perlis, R. H., . . . Wray, N. R. (2013). Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet, 45(9), 984-994. doi:10.1038/ng.2711 Leo, D., & Gainetdinov, R. R. (2013). Transgenic mouse models for ADHD. Cell Tissue Res, 354(1), 259-271. doi:10.1007/s00441-013-1639-1 Li, K. C. (2002). Genome-wide coexpression dynamics: theory and application. Proc Natl Acad Sci U S A, 99(26), 16875-16880. doi:10.1073/pnas.252466999 Li, K. C., Palotie, A., Yuan, S., Bronnikov, D., Chen, D., Wei, X., . . . Peltonen, L. (2007). Finding disease candidate genes by liquid association. Genome Biol, 8(10), R205. doi:10.1186/gb-2007-8-10-r205 Li, Z., Chang, S. H., Zhang, L. Y., Gao, L., & Wang, J. (2014). Molecular genetic studies of ADHD and its candidate genes: a review. Psychiatry Res, 219(1), 10-24. doi:10.1016/j.psychres.2014.05.005 Lin, C. C., Lai, M. S., Syu, C. Y., Chang, S. C., & Tseng, F. Y. (2005). Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Assoc, 104(3), 157-163. Mannuzza, S., Klein, R. G., Bessler, A., Malloy, P., & LaPadula, M. (1998). Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry, 155(4), 493-498. doi:10.1176/ajp.155.4.493 Martin-Latry, K., & Begaud, B. (2010). Pharmacoepidemiological research using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf, 19(3), 256-265. doi:10.1002/pds.1912 McIntyre, R. S., Kennedy, S. H., Soczynska, J. K., Nguyen, H. T. T., Bilkey, T. S., Woldeyohannes, H. O., & Muzina, D. J. (2010). Attention-Deficit/Hyperactivity Disorder in Adults With Bipolar Disorder or Major Depressive Disorder: Results From the International Mood Disorders Collaborative Project. Primary Care Companion to The Journal of Clinical Psychiatry, 12(3). doi:10.4088/PCC.09m00861gry Meinzer, M. C., Pettit, J. W., & Viswesvaran, C. (2014). The co-occurrence of attention-deficit/hyperactivity disorder and unipolar depression in children and adolescents: a meta-analytic review. Clin Psychol Rev, 34(8), 595-607. doi:10.1016/j.cpr.2014.10.002 Monfared, A. A., & Lelorier, J. (2006). Accuracy and validity of using medical claims data to identify episodes of hospitalizations in patients with COPD. Pharmacoepidemiol Drug Saf, 15(1), 19-29. doi:10.1002/pds.1131 Nussbaum, N. L. (2012). ADHD and female specific concerns: a review of the literature and clinical implications. J Atten Disord, 16(2), 87-100. doi:10.1177/1087054711416909 Oades, R. D. (2008). Dopamine-serotonin interactions in attention-deficit hyperactivity disorder (ADHD). Prog Brain Res, 172, 543-565. doi:10.1016/s0079-6123(08)00926-6 Owen, M. J. (2012). Intellectual disability and major psychiatric disorders: a continuum of neurodevelopmental causality. Br J Psychiatry, 200(4), 268-269. doi:10.1192/bjp.bp.111.105551 Owen, M. J., O'Donovan, M. C., Thapar, A., & Craddock, N. (2011). Neurodevelopmental hypothesis of schizophrenia. Br J Psychiatry, 198(3), 173-175. doi:10.1192/bjp.bp.110.084384 Park, J. H., Bang, Y. R., & Kim, C. K. (2014). Sex and Age Differences in Psychiatric Disorders among Children and Adolescents: High-Risk Students Study. Psychiatry Investig, 11(3), 251-257. doi:10.4306/pi.2014.11.3.251 Partridge, B., Lucke, J., & Hall, W. (2012). Public attitudes towards the acceptability of using drugs to treat depression and ADHD. Aust N Z J Psychiatry, 46(10), 958-965. doi:10.1177/0004867412450755 Peralta, V., de Jalon, E. G., Campos, M. S., Zandio, M., Sanchez-Torres, A., & Cuesta, M. J. (2011). The meaning of childhood attention-deficit hyperactivity symptoms in patients with a first-episode of schizophrenia-spectrum psychosis. Schizophr Res, 126(1-3), 28-35. doi:10.1016/j.schres.2010.09.010 Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007). The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry, 164(6), 942-948. doi:10.1176/ajp.2007.164.6.942 Polanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C., & Rohde, L. A. (2014). ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol, 43(2), 434-442. doi:10.1093/ije/dyt261 Quinn, P. O., & Madhoo, M. (2014). A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis. The primary care companion for CNS disorders, 16(3). Rapoport, J. L. (2013). Pediatric psychopharmacology: too much or too little? World Psychiatry, 12(2), 118-123. doi:10.1002/wps.20028 Ross, R. G. (2006). Psychotic and manic-like symptoms during stimulant treatment of attention deficit hyperactivity disorder. Am J Psychiatry, 163(7), 1149-1152. doi:10.1176/appi.ajp.163.7.1149 Sadasivan, S., Pond, B. B., Pani, A. K., Qu, C., Jiao, Y., & Smeyne, R. J. (2012). Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One, 7(3), e33693. doi:10.1371/journal.pone.0033693 Safer, D. J. (2015). Is ADHD Really Increasing in Youth? J Atten Disord. doi:10.1177/1087054715586571 Sharp, S. I., McQuillin, A., & Gurling, H. M. (2009). Genetics of attention-deficit hyperactivity disorder (ADHD). Neuropharmacology, 57(7-8), 590-600. doi:10.1016/j.neuropharm.2009.08.011 Shyu, Y. C., Lee, S. Y., Yuan, S. S., Yang, C. J., Yang, K. C., Lee, T. L., & Wang, L. J. (2016). Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine. Clin Ther, 38(3), 595-602. doi:10.1016/j.clinthera.2016.01.015 Shyu, Y. C., Yuan, S. S., Lee, S. Y., Yang, C. J., Yang, K. C., Lee, T. L., & Wang, L. J. (2015). Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. Schizophr Res, 168(1-2), 161-167. doi:10.1016/j.schres.2015.08.033 Smith, P. B., Benjamin, D. K., Jr., Murphy, M. D., Johann-Liang, R., Iyasu, S., Gould, B., . . . Rodriguez, W. (2008). Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics, 122(3), e628-633. doi:10.1542/peds.2008-0585 Suissa, S. (2008). Immortal time bias in pharmaco-epidemiology. Am J Epidemiol, 167(4), 492-499. doi:10.1093/aje/kwm324 Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012). Genetic architectures of psychiatric disorders: the emerging picture and its implications. Nat Rev Genet, 13(8), 537-551. doi:10.1038/nrg3240 Sylvestre, M. P., & Abrahamowicz, M. (2008). Comparison of algorithms to generate event times conditional on time-dependent covariates. Stat Med, 27(14), 2618-2634. doi:10.1002/sim.3092 Sylvestre, M. P., & Abrahamowicz, M. (2009). Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. Stat Med, 28(27), 3437-3453. doi:10.1002/sim.3701 Taurines, R., Schmitt, J., Renner, T., Conner, A. C., Warnke, A., & Romanos, M. (2010). Developmental comorbidity in attention-deficit/hyperactivity disorder. Atten Defic Hyperact Disord, 2(4), 267-289. doi:10.1007/s12402-010-0040-0 Tebartz van Elst, L., Pick, M., Biscaldi, M., Fangmeier, T., & Riedel, A. (2013). High-functioning autism spectrum disorder as a basic disorder in adult psychiatry and psychotherapy: psychopathological presentation, clinical relevance and therapeutic concepts. Eur Arch Psychiatry Clin Neurosci, 263 Suppl 2, S189-196. doi:10.1007/s00406-013-0459-3 Thapar, A., & Cooper, M. (2016). Attention deficit hyperactivity disorder. The Lancet, 387(10024), 1240-1250. doi:10.1016/s0140-6736(15)00238-x Thomas, R., Sanders, S., Doust, J., Beller, E., & Glasziou, P. (2015). Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics, 135(4), e994-1001. doi:10.1542/peds.2014-3482 Treceno, C., Martin Arias, L. H., Sainz, M., Salado, I., Garcia Ortega, P., Velasco, V., . . . Carvajal, A. (2012). Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y Leon (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiol Drug Saf, 21(4), 435-441. doi:10.1002/pds.2348 Tsan, Y. T., Lee, C. H., Wang, J. D., & Chen, P. C. (2012). Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol, 30(6), 623-630. doi:10.1200/jco.2011.36.0917 Ushijima, H., Usami, M., Saito, K., Kodaira, M., & Ikeda, M. (2012). Time course of the development of depressive mood and oppositional defiant behavior among boys with attention deficit hyperactivity disorder: differences between subtypes. Psychiatry Clin Neurosci, 66(4), 285-291. doi:10.1111/j.1440-1819.2012.02340.x van de Loo-Neus, G. H., Rommelse, N., & Buitelaar, J. K. (2011). To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended? Eur Neuropsychopharmacol, 21(8), 584-599. doi:10.1016/j.euroneuro.2011.03.008 Wallis, D., Russell, H. F., & Muenke, M. (2008). Review: Genetics of attention deficit/hyperactivity disorder. J Pediatr Psychol, 33(10), 1085-1099. doi:10.1093/jpepsy/jsn049 Wang, L. J., Lee, S. Y., Yuan, S. S., Yang, C. J., Yang, K. C., Huang, T. S., . . . Shyu, Y. C. (2016). Prevalence rates of youths diagnosed with and medicated for ADHD in a nationwide survey in Taiwan from 2000 to 2011. Epidemiol Psychiatr Sci, 1-11. doi:10.1017/S2045796016000500 Wang, L. J., Lee, S. Y., Yuan, S. S., Yang, C. J., Yang, K. C., Lee, T. L., & Shyu, Y. C. (2016). Impact of negative media publicity on attention-deficit/hyperactivity disorder medication in Taiwan. Pharmacoepidemiol Drug Saf, 25(1), 45-53. doi:10.1002/pds.3907 Wang, L. J., Yang, K. C., Lee, S. Y., Yang, C. J., Huang, T. S., Lee, T. L., . . . Shyu, Y. C. (2016). Initiation and Persistence of Pharmacotherapy for Youths with Attention Deficit Hyperactivity Disorder in Taiwan. PLoS One, 11(8), e0161061. doi:10.1371/journal.pone.0161061 Wilens, T. E., Biederman, J., & Spencer, T. J. (2002). Attention deficit/hyperactivity disorder across the lifespan. Annu Rev Med, 53, 113-131. doi:10.1146/annurev.med.53.082901.103945 Yoshida, K., Solomon, D. H., & Kim, S. C. (2015). Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol, 11(7), 437-441. doi:10.1038/nrrheum.2015.30 Yuce, M., Zoroglu, S. S., Ceylan, M. F., Kandemir, H., & Karabekiroglu, K. (2013). Psychiatric comorbidity distribution and diversities in children and adolescents with attention deficit/hyperactivity disorder: a study from Turkey. Neuropsychiatr Dis Treat, 9, 1791-1799. doi:10.2147/NDT.S54283 Zalsman, G., Brent, D. A., & Weersing, V. R. (2006). Depressive disorders in childhood and adolescence: an overview: epidemiology, clinical manifestation and risk factors. Child Adolesc Psychiatr Clin N Am, 15(4), 827-841, vii. doi:10.1016/j.chc.2006.05.002 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77837 | - |
dc.description.abstract | 注意力不足過動症(Attention Deficit/Hyperactivity Disorder, ADHD)是一種神經精神疾病,其常見症狀為注意力不集中、過動與衝動。ADHD患者常伴隨著其他精神障礙如對立反抗症(Oppositional Defiant Disorder, ODD)、行為規範障礙(Conduct Disorder, CD)與焦慮症 (Anxiety Disorder, AD)。ADHD患者是否有更高的風險罹患重度憂鬱症(Major depressive disorder, MDD)及思覺失調症(Schizophrenia)則是長久以來的爭議話題。不同的結論可能來自於不同的實驗設計、不同的人群取樣及不同的研究區間。
近年來,由於藥物流行病學的發展及台灣健保資料庫的建立,我們有機會利用大量長期的保險請款資料,進行ADHD病患的長期罹病追蹤研究。我們也可藉由長期的開藥記錄,研究藥物的長期使用是否會影響ADHD罹患重度憂鬱症與思覺失調症的風險。然而,藥物使用量的分析是非常複雜的,我們需要更精細的統計分析方法,來得到更適當的風險估計。 在本篇研究中,我們先從世代研究開始,探討ADHD患者是否有更高的風險罹患重度憂鬱症(第二章)及思覺失調症(第三章);然後我們對於健保資料庫中有ADHD確診記錄的病患族群進行完整的族群描述,包含盛行率與用藥特徵分析(第四章);鑒於ADHD與其他精神疾病可能有基因上的相似性,我們也回顧了ADHD的基因體學發展,並嘗試使用Liquid association分析,探索更多潛在與ADHD有關的基因(第五章);最後我們回到藥物流行病學統計方法,討論時間相依共變數之存活分析、累計藥量的估算,以及現有統計方法的限制,並提出改善的方法(第六章)。 | zh_TW |
dc.description.abstract | Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder. Patients diagnosed with ADHD were also accompanied with other comorbidities such as oppositional defiant (ODD), conduct disorder (CD), and Anxiety Disorder (AD). It has been debated for decades that whether patients with ADHD diagnosis are associated with subsequent diagnosis of depressive disorders or psychotic disorders. Inconsistent results from these studies may be caused by differences in diagnostic criteria, follow-up lengths, sample sizes, and study designs.
In recent years, with the development of pharmacoepidemiology and the establishment of National Health Insurance Research Database (NHIRD), we are now able to perform national-wide cohort studies by analyzing massive claims data from National Health Insurance Research Database (NHIRD). By analyzing long-term prescription records, we are also able to study that whether medication treatments in ADHD patients affect the risk of developing subsequent depressive disorders or psychotic disorders. However, the analyses of drug usage are complex. We need more delicate statistical models to get the better hazard estimates. In this dissertation, we began with studying whether ADHD patients have higher risk of developing subsequent depressive disorders (Chapter 2) or psychotic disorders (Chapter 3). Then we summarized the diagnosis rate and prescription patterns of ADHD in recent years (Chapter 4). In view of the genetic similarity between ADHD and other mental disorders, we reviewed candidate genes reported by family or case-control studies. Then we tried to find more potential candidate genes by performing liquid association analysis (Chapter 5). Finally, we reviewed the study designs, statistical biases common in pharmacoepidemiology. We discussed the statistical methods regarding cumulative exposure as time-dependent variable in Cox proportional hazard regression and the limitation of current methods. Then we provided a new procedure to improve the analysis results (chapter 6). | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T14:35:45Z (GMT). No. of bitstreams: 1 ntu-106-D01b48003-1.pdf: 3997579 bytes, checksum: 01ee255ab6b527f6d7ddadee0fb91d14 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書 #
誌謝 i 中文摘要 ii ABSTRACT iv CONTENTS vi LIST OF FIGURES ix LIST OF TABLES xi Chapter 1 Introduction 1 1.1 Current status on ADHD research 1 1.2 Introduction to NHIRD 2 1.3 Using NHIRD to conduct a pharmacoepidemiological study 5 Chapter 2 Risk of developing depressive disorder 6 2.1 Introduction 6 2.2 Method 8 2.2.1 Data source and ADHD patients selection 8 2.2.2 Control group selection and matching procedure 10 2.2.3 ADHD subtypes, outcomes, comorbidities, and medication 11 2.2.4 Statistical analysis 12 2.3 Results 13 2.4 Discussion 14 2.5 Limitations 17 Chapter 3 Risk of developing psychotic disorder 22 3.1 Introduction 22 3.2 Method 23 3.2.1 Data processing 23 3.2.2 Statistical analysis 24 3.3 Results 27 3.4 Discussion 28 Chapter 4 ADHD diagnosis rate and prescription patterns in Taiwan 33 4.1 Introduction 33 4.2 ADHD diagnosis rate and prescription rate in Taiwan 35 4.3 Initiation and persistence of pharmacotherapy for youths with ADHD in Taiwan 38 4.4 Other patterns regarding ADHD diagnosis and drug prescription 40 Chapter 5 ADHD genetics 49 5.1 Candidate genes in ADHD 49 5.2 Genetic relationship between ADHD and other mental diseases 51 5.3 Find ADHD candidate genes by liquid association 51 5.4 Discussion 63 Chapter 6 Statistical Methods in Pharmacoepidemiology 66 6.1 Study design, bias, and confounding 66 6.1.1 Immortal time-biases 66 6.1.2 Confounding by indication and New-user design 69 6.2 Modeling cumulative drug exposure 71 6.2.1 Staggered entry and cumulative exposure 71 6.2.2 Different type of time-dependent drug exposures 74 6.2.3 Parametric method for weighted cumulative drug exposures 76 6.2.4 Non-parametric method for weighted cumulative drug exposures 77 6.3 Assessing time-dependent cox model and flexible WCE model on ADHD drug history analysis 78 6.3.1 Prepare ADHD drugs history data 79 6.3.2 Apply conventional Time-dependent Cox models and WCE model 81 6.3.3 Assess the performance between multivariate time-dependent Cox model and WCE model 85 6.4 Discussion 91 REFERENCE 93 | |
dc.language.iso | en | |
dc.title | 注意力不足過動症之藥物流行病學危險因子及與其它精神疾病之關聯性研究 | zh_TW |
dc.title | Pharmacoepidemiological factors for Attention-deficit/hyperactivity disorder (ADHD) and the association with other mental disease development | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 袁新盛(Shin-Sheng Yuan),陳璿宇(Hsuan-Yu Chen),徐于喬(Yu-Chiau Shyu),黃挺碩 | |
dc.subject.keyword | 注意力不足過動症,ADHD,藥物流行病學,時間相依共變數之存活分析,累計藥量, | zh_TW |
dc.subject.keyword | ADHD,pharmacoepidemiology,time-dependent covariates,cumulative effects, | en |
dc.relation.page | 100 | |
dc.identifier.doi | 10.6342/NTU201703725 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2017-08-20 | |
dc.contributor.author-college | 生命科學院 | zh_TW |
dc.contributor.author-dept | 基因體與系統生物學學位學程 | zh_TW |
顯示於系所單位: | 基因體與系統生物學學位學程 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-D01b48003-1.pdf 目前未授權公開取用 | 3.9 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。